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Background: Vascular endothelial growth factor (VEGF) is a key angiogenic factors. It plays an important role in
both physiologic and pathologic angiogenesis and increases permeability across the vessels. Using antibody phage
display technology, we obtained a novel anti-VEGFA IgG, named as FD006. In this study, the pharmacological
characteristics and efficacy of FD006 in corneal neovascularization (CoNV) were evaluated.
Results: FD006 was predicted to have similar binding mode to bevacizumab. Experimental analysis showed that
the binding ability of FD006 seemed a little stronger than bevacizumab, for the EC50 of FD006 to bind VEGF
analyzed by ELISA was about 0.037 μg/mL while that of bevacizumab was 0.18 μg/mL. Binding kinetics assays
showed similar results that FD006 possessed 2-fold higher affinity to bind VEGF than bevacizumab due to slower
dissociation rate of FD006; meanwhile, FD006 inhibited the VEGF-induced proliferation of HUVEC with an IC50 value
of 0.031 ± 0.0064 μg/ml, which seemed similar or a litter better than bevacizumab (0.047 ± 0.0081 μg/ml). The
subconjunctival administration of FD006, bevacizumab or dexamethasone could significantly inhibit the growth of
CoNV contrasting to N.S (p < 0.01). At the early stage, FD006 showed better inhibitory effect on the growth of CoNV
compared with bevacizumab (p < 0.05). Western blot analysis showed that FD006 could inhibit the expression of
VEGF, VEGFR-1, VEGFR-2, MMP-9 and ICAM-1, which could explain its favorable anti-angiogenic activity.
Conclusions: The pharmacological characteristics of FD006 were similar or even a little better than bevacizumab in
inhibiting corneal neovascularization.
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Corneal avascularity is necessary for the preservation of
corneal transparency and optimal vision [1]. There is a
dynamic balance between pro- and anti-angiogenic fac-
tors in the cornea that plays a key role in maintaining
avascularity. Under normal physiologic conditions, the
process of angiogenesis is well controlled, reflecting a
perfect balance of endogenous growth factors and sup-
pressors. However, in the condition of persistent hyp-
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unless otherwise stated.cell deficiency, the pro-angiogenic growth factors out-
number angiogenesis inhibitors, the balance shifts in
favor of angiogenesis, and then the corneal angiogenic
privilege could be destroyed [2,3]. Although new blood
vessel growth in response to ischemic conditions is to
repair the injury, pathologic corneal neovascularization
(CoNV) and hyperpermeability can cause decreased vision
and failure of transplantation. CoNV is a sight-threatening
condition, which is also a challenge for ophthalmologists.
The inhibitory effects of steroids, cyclosporine, thalido-
mide, photodynamictherapy, conjunctival limbal allograft
and fine needle diathermy for CoNV vary in clinical and
experimental use [4-9]. They are not always effective,
sometimes may induce complications.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Wang et al. BMC Biotechnology 2014, 14:17 Page 2 of 9
http://www.biomedcentral.com/1472-6750/14/17Angiogenesis, the process by which new vessels sprout
from pre-existing vasculature, has become the subject of
intense research in recent years and therapies that dir-
ectly target key factors of neovascular formation are
promising. Among the angiogenic factors, vascular
endothelial growth factor (VEGF) plays an important
role in both physiologic and pathologic angiogenesis and
increases permeability across the vessels. Extensive re-
search studies focus on the VEGF families and receptors
[10,11]. Given that several studies have demonstrated
that the secretion and receptor expression of VEGF were
increased during the neovascularization of the cornea,
specific molecules have been targeted for drug develop-
ment and have drawn much attention recently [10-12].
The targeted inhibition of VEGF provides ophthalmolo-
gists with an angiogenesis-specific pharmacological ap-
proach to treating CoNV and deserves to be evaluated.
There are many VEGF inhibitors which are in advanced
clinical use for ocular neovascularization, such as Lucen-
tis, Macugen and bevacizumab/Avastin. Administration
of these drugs in CoNv has been associated with promis-
ing results [13-15].
In our previous work, we screened out a novel anti-
VEGF antibody from a natural human scFv phage library
which was constructed in our lab. Then, the recombinant
vector to express the full antibody was constructed and
transfected into mammalian cells. The full IgG, named as
FD006, was prepared for further studies. The purpose of
the present study was to investigate the pharmacological
characteristics and efficacy of FD006 both in vitro and
in vivo.Results
The predicted binding mode of FD006 was similar to
bevacizumab
Using antibody phage display library, we obtained a
novel anti-VEGFA antibody, named as FD006. After se-
quencing, the amino acid residues of the variable region
in FD006 were determined as shown in Figure 1A.
Using computer-guided homology modeling method,
the Stable 3-D structure of FD006 variable region was
constructed and shown in Figure 1B. Based on the
crystal structure of VEGFA, the complex structure of
VEGFA and FD006 was constructed and optimized
(Figure 1C) using computer-guided molecular docking
method. Using interactive graphics and the hard-sphere
approximation for atoms, we found that the FD006 vari-
able region was fitted into the binding site of VEGFA
which identified by bevacizumab. The binding mode of
FD006, e.g. binding energy and epitope, was analyzed
and shown in Table 1, which showed that the binding
mode between FD006 and VEGF was similar to bevaci-
zumab and VEGF.FD006 possessed similar or even higher affinity than
bevacizumab
ELISA assay was performed to determine the antigen-
binding specificity of FD006. As shown in Figure 2A, it
was shown that both bevacizumab and FD006 could
bind to VEGF on a dose-dependent manner. In addition,
the EC50 of FD006 was about 0.037 μg/mL while that of
bevacizumab was 0.18 μg/mL, suggesting that FD006
might possess stronger binding ability than bevacizumab
(5-fold). Further experiments indicated the interacting
kinetics of two mAbs to bind to VEGF (Figure 2B), dis-
playing approximately 2-fold higher affinity of FD006
than bevacizumab (Table 2) due to its slower dissoci-
ation rate; besides, the inhibitory ability of FD006 against
the VEGF-induced cell proliferation in HUVEC was
identified. The IC50 value of FD006 was approximately
0.031 ± 0.0064 μg/ml, indicating its somewhat better
antiangiogenic activity of FD006 than bevacizumab
(0.047 ± 0.0081 μg/ml) (Figure 2C).
FD006 inhibited in vivo neovascularization in CoNV
Alkali-induced CoNV model is a simple model system
for the study of neovascularization. After the alkali-
soaked filter paper was removed from the cornea, the
central cornea appeared opaque with a clear margin.
After modeling, vessels began sprouting into the cornea
from the limbus. It was demonstrated that the subcon-
junctival administration of FD006, bevacizumab and
dexamethasone could all significantly inhibit CoNV in
NaOH cauterized rats compared with the control group
(p < 0.01) (Figures 3 and 4); furthermore, compared with
bevacizumab, FD006 was a little more effective on inhi-
biting CoNV to reduce the length and area of the cor-
neal neovasculature at day 3 and day 7 (0.01 < P < 0.05).
However, since day 14, there was no obvious difference
between the two groups (p > 0.05). Meanwhile, the two
antibodies were less effective than dexamethasone
(p < 0.01). Typical HE staining images of the rats’ CoNV
were shown in Figure 4, which also displayed weaker
vascularization in the FD006 group, bevacizumab group
and dexamethasone group contrasting to that in the
control group (Figure 5).
FD006 downregulated the expression of
neovascularization-related molecules in the cornea
According to western blot analysis, the subconjunctival
administration of FD006 or bevacizumab significantly
decreased the protein expression of VEGF, VEGFR-1,
VEGFR-2, MMP-9 and ICAM-1, while 0.9% NaCl treated
group and solvent group displayed visibly high expression
of the above factors in the cornea (Figure 6). It might be
the possible mechanism of FD006’s inhibitory ability
against neovascularization in vivo, indicating that FD006
might be a favorable anti-angiogenic candidate drug.
Figure 1 Theoretical analysis of FD006 to bind VEGF. A: The amino acid residues and CDR region classification of FD006 (versus Avastin/
bevacizumab); B: The 3-D structure of variable region in FD006 using computer-guided homology modeling and molecular dynamics methods.
The yellow ribbon denoted the light chain variable region and the red ribbon denoted the heavy chain variable region; C: The 3-D complex
structure of FD006 variable region and VEGFA obtained from computer-guided molecular docking and dynamics methods. The upper red ribbon
denoted VEGF, the lower left (blue) ribbon was FD006-VL and the lower right (green and yellow) denoted FD006-VH.
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The normal cornea is an avascular structure. The forma-
tion of neovascularization may be a physiological re-
sponse to various stimuli; however, the chronic and
persistent upregulation of pro-angiogenic factors may
result in pathological CoNV, which can lead to blindness.Table 1 The predicted binding energy (kCal/mol) and





FD006-VEGF −168.24 F17M18D19, Y21Q22R23, Y25, L66E67,
N100K101
bevacizumab-VEGF −156.35 F17M18D19, Y21Q22R23, Y25, K101For it was reported that VEGF is required for inflamma-
tory neovascularization and a crucial endogenous corneal
angiogenic factor, VEGF was confirmed as the key target
for blocking the cascade of neovascular formation
[16,17]. VEGF is a vascular endothelial cell mitogen and
one of the key regulators of angiogenesis in various
physiological and pathological conditions [14]. By bind-
ing to VEGFR, VEGF triggers its tyrosine phosphoryl-
ation and induces a signaling cascade that promotes
growth, survival, migration, differentiation of endothelia
cells as well as mobilizing endothelial progenitor cells
from the bone marrow into the peripheral circulation
[16-18]. The angiogenic activity of VEGF is believed to
be regulated by two high affinity receptor tyrosine
kinases, VEGFR-1 (fms-like tyrosine kinase, Flt-1) and
VEGFR-2 (kinase insert domain receptor, Flk-1), which is
Figure 2 Antigen binding identification of FD006 to bind VEGF. (A) The binding activity of FD006 by ELISA; (B) Affinity detection of FD006
by binding kinetics assays; (C) The inhibitory effects of FD006 on VEGF-induced human umbilical vein endothelial cell (HUVEC) proliferation. The
proliferation percentage was calculated using the formula ODsample/ODuntreated × 100 %. Data points represent the mean 6 SD of values acquired
in duplicate.
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of VEGF. Although the complications of dexamethasone
such as cataract and secondary glaucoma have limited its
clinical use, it is still a powerful anti-VEGF agent; bevaci-
zumab is also considered as an effective anti-VEGF agent
that can bind to soluble VEGF, preventing receptor bind-
ing [19,20].
We discovered that the protein expression of ICAM-1
and MMP-9 was significantly higher in the control
groups than in the other groups. FD006 reduced the ex-
pression of ICAM-1 and MMP-9 compared with the
control groups (Figure 6). ICAM-1 (Intercellular adhe-
sion molecule 1) is one of cell surface glycoproteins that
are typically expressed on endothelial cells. ICAMs may
play a critical role in regulating leukocyte migration andTable 2 Interacting kinetics of bevacizumab and FD006
binding to VEGF
KD (M) Kon (1/Ms) Kdis (1/s) Full R2
bevacizumab 6.50E-10 1.75E + 05 1.02E-04 0.992536
FD006 3.11E-10 1.48E + 05 4.59E-05 0.992964accumulation at sites of inflammation, thus generating
inflammatory response and damage to tissue [21]. Cor-
neal fibroblasts expressed ICAM-1 and VCAM-1 when
activated with IL-4 and TNF-alpha [22]. Luo et al. dis-
covered that VEGF and b-FGF can facilitate the expres-
sion of ICAM-1 [23]. Therefore we inferred that the
expression level of ICAM-1 was lower in FD006 group
because there may be a feedback reaction where the de-
creased VEGF expression influences the release of
ICAM-1 after FD006 blocked the VEGF signaling.
MMPs play indispensable roles in the formation of
CoNV and are one of the most potent proangiogenic fac-
tors. MMP-9, also known as gelatin B, plays an important
role in degrading the ECM and basement membrane dur-
ing organizational restructuring and angiogenesis. MMPs
can promote the migration of endothelial cells by
destroying connections between the cells and the extra-
cellular matrix [24]. Particularly, the synergistic actions
of MMPs and VEGF have been discovered in angiogen-
esis, and studies have already demonstrated that VEGF
and MMPs influence each other during angiogenesis.
MMP can enhance VEGF release and modulate VEGF
Figure 3 The mean length and area of the corneal neovascularization. 0.9% NaCl treated group and solvent group were set as controls.
Results are represented as mean ± SEM. *p < 0.05, **p < 0.01.
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lease of the MMPs and decreases the release of the tissue
inhibitor of metalloproteinase, whereas MMPs activate the
angiogenic activity of VEGF. We believe that, among
ICAM-1, MMP-9 and VEGF, there is a cascade of chainFigure 4 Typical images of rat corneal neovascularization
caused by alkali burn. The dotted lines represent the margin of
the corneal neovascularization.reactions that influence each other. However, our hypoth-
eses require further investigation.
In this study, we screened and predicted the novel anti-
VEGF monoclonal antibody FD006 to have similar affinity
to bevacizumab (Figure 1 and Table 1). Further experi-
ments testified that both bevacizumab and FD006 could
bind to VEGF specifically on a dose-dependent manner;
meanwhile, FD006 showed somewhat stronger affinity to
bind VEGF than bevacizumab by both ELISA (5-fold)
and binding kinetics assays (2-fold) mainly because of its
slower dissociation rate (Table 2). In principle, the higher
affinity of anti-VEGF means higher efficiency to neutralize
VEGF; furthermore, FD006 seemed to have a better
inhibitory effect on the VEGF-induced proliferation of
HUVEC than bevacizumab, which was consistent with
antigen binding assays (Figure 2).
The alkali burn-induced CoNV model has been widely
used to investigate the mechanism of corneal neovascu-
lar formation. Here, this method also induced CoNV
successfully. Several studies reported that bevacizumab
was more effective via subconjunctival administration
for CoNV compared with via topical eye drops [19,20],
therefore in this study FD006 was subconjunctivally
injected in alkali-burn induced corneal neovascularizai-
ton to evaluate its biological properties in vivo. It was
demonstrated that FD006 could inhibit corneal neovas-
cular formation. Particularly, during the early stage after
Figure 5 Hematoxylin and eosin (HE) staining observation of
corneas. At day 7, corneal neovascularization of various sizes (black
arrowhead) were present in the superficial central corneal stroma
after alkali burn (×200) and neovascularization containing RBCs in
the corneal stroma were indicated with black arrowheads. Cornea
stroma exhibited edema and mononuclear inflammatory response.
In this plane of section, the corneal epithelium is relatively
normal. Bar = 100 μm.
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(Figures 3, 4 and 5). The reason might be the higher abil-
ity of FD006 to bind VEGF. However, at the late stages,
FD006 and bevacizumab had an equal therapeutic effect
on inhibiting CoNV. Besides, FD006 significantly de-
creased the expression of VEGF, VEGFR-1, VEGFR-2,
ICAM-1, and MMP-9 in cornea compared with the con-
trol group (Figure 6), explaining partially why FD006 had
satisfactory anti-neovascularization effect.Figure 6 The protein expression of neovascularization-related
signal molecules in the cornea. β-actin served as an internal
standard. The protein expression of VEGF, MMP-9, VEGFR-1, VEGFR-2
and ICAM-1 in the cornea was significantly weaker in antibody- or
dexamethasone- treated samples.Conclusion
This study displayed the pharmacological characteris-
tics of FD006, which were similar or a little superior
to bevacizumab, such as higher affinity, better anti-
neovascularization function in vitro and in vivo, indi-
cating that FD006 might be a promising agent in the
treatment of human CoNV in the future.
Methods
Chemicals and antibodies
FD006 is a potent recombinant humanized monoclo-
nal antibody directed against VEGF and prepared in
our lab. The commercial anti-VEGF antibody bevacizu-
mab (Avastin, 100 mg/4 ml) was purchased from Roche
Pharmaceutical (Genentech, South San Francisco, USA),
analyzed in our theoretical platform and set as positive
control. Bevacizumab was dialyzed with the same solvent
as FD006 in this study.
Computational modeling and docking
Based on the variable heavy (VH) and light chain (VL)
sequences of FD006, sequence alignmment were per-
formed using BLASTp (http://www.ncbi.nlm.nih.gov)
software with PDB database. And then, the 3-D struc-
ture of the antibody FD006 variable region was con-
structed using computer-guided homology modeling
method based on the crystal structures of VH domain of
B20-4 Fab (PDB code: 2FJH) and VL domain of B20-4
Fab (PDB code: 2FJH). After constructing the backbone
of the Fv fragment, the side chains were replaced using
rotamer libraries and algorithm implemented in the
Homology package of InsightII 2000 (MSI, San Diego,
CA). Furthermore, the structure of the FD006 variable
region was optimized under CVFF force field [29] using
molecular dynamics method. On the basis of the crystal
structure of the extracellular domain of VEGFA (PDB
code: 2FJH [30], the partial charges of the VEGFA and
FD006 Fv fragment were assigned. According to the
crystal complex structure of VEGFA and its functional
antibody bevacizumab (PDB code: 2FJH), the FD006 Fv
fragment was docked manually into the binding site of
VEGFA. The antigen-antibody complex was relaxed by
energy minimization and subsequent molecular dynamic
simulations in vacuo using the CVFF forcefield. Molecu-
lar dynamic simulations were performed using the NVT
ensemble of the Discover 3.0 package (MSI). The bind-
ing energy and identified domain between FD006 and
VEGFA were analyzed with distance geometry and com-
puter graphics technology.
ELISA analysis
ELISA plates were coated with 100 μl/well 0.5 μg/ml
VEGF. Bevacizumab or FD006 were diluted (10, 2, 0.4,
0.08, 0.016 and 0.0032 μg/ml) and added for 2 hours’
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Peroxidase-conjugated affinipure goat anti-human im-
munoglobulin G (IgG) was added as the secondary anti-
body for 45 minutes at room temperature (RT for short,
the same below). Binding signals were visualized using
o-phenylenediamine dihydrochloride (OPD) substrate
and the light absorbance was measured with an ELISA
reader at 492 nm.
Binding kinetics assays
The binding kinetics of bevacizumab or FD006 to VEGF
was measured using Bio-Layer Inter-Ferometry on Octet
RED (Fortebio, USA). The assay was conducted at 30°C
in PBS buffer. Sensor tips were pre-wet for 15 mins in
buffer immediately prior to use, and the microplates
were filled with 200 μl per well of diluted samples
(VEGF) or buffer and agitated at 1000 rpm. The anti-
human IgG biosensor were pre-saturated with bevacizu-
mab or FD006 (10 μg/ml) and washed in buffer for
120 seconds, and then transferred to VEGF at concen-
trations of 10 μg/ml, 3 μg/ml and 1 μg/ml. The VEGF
association and dissociation rates were measured for
5mins and 10mins, respectively. The Kinetics parameters
(Kon and Koff ) and affinities (KD) were calculated from
a non-linear global fit using the Octet analysis software.
Multiple independent measurements were performed.
Proliferation assays
Human umbilical vein endothelial cells (HUVECs) (1 ×
104 cells/100 μL/well) were seeded in 96-well plates and
cultured at 37 for 14 h with Endothelial Cell Medium
(ScienCell) supplemented with 5% heat-inactivated FCS,
100 U/ml penicillin, 100U/ml streptomycin, and endo-
thelial cell growth supplement (ScienCell). After low-
serum starvation overnight, cells were treated with
different concentrations of FD006 or bevacizumab which
were pre-incubated with 10 ng/ml VEGF for 30 minutes
and incubated at 37, 5% CO2 for 72 hours. Then, 10 μl
CCK8 was added to each well and incubated for another
4 hours. The absorbance was measured by spectropho-
tometer at 450 nm to determine the cell viability.
Animals
Ninety male Sprague–Dawley rats (6–8 weeks, 180-200 g)
were obtained from the Laboratory Animal Centre in
Academy of military medical sciences. The right eyes of
the animals were used for experiments, and the left eyes
were left intact. All rats were carefully examined before the
procedure using a slit lamp microscope and the corneas
with any defects, new vessels, or cataract were excluded.
The animal studies were approved by Animal Ethics
Committee of Institute of Basic Medical Sciences. All
procedures involving animal eye studies were conductedstrictly in accordance with the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research.
Alkali burn model
Prior to the procedure, the rats were anesthetized using an
intraperitoneal injection of 3.5 ml/kg 10% chloral hydrate
(General Hospital of PLA, Beijing), and the eyes were
treated with a topical application of 0.5% proparacaine
hydrochloride (Alcain; Alcon, USA). Then, a 3 mm diam-
eter Whatman 3# filter paper was soaked in 5 μL of 1 M
sodium hydroxide for 60 s and then placed in the center
of the cornea for 40 s. The burned area and conjunctival
sac was then irrigated with 60 ml saline for 1 minute.
Animal treatment
After modeling, ninety rats were randomly divided into
five groups (eighteen rats per group) and received a sub-
conjunctival injection with 0.05 ml per rat of (1) 0.9%
NaCl, (2) solvent, (3) 0.1% dexamethasone (Dexame-
thasone sodium phosphate, NCPC.LTD, China), (4) 25
mg/ml bevacizumab and (5) 25 mg/ml FD006 in the su-
perior temporal conjunctiva on the day after modeling.
All chemical burns and treatments were performed by
one investigator. The operator was blinded to the treat-
ment group from which each cornea was derived. At
postoperative days 3, 7, 14, 21 and 28, the eyes were har-
vested for further studies after the rats were sacrificed
with an overdose of 10% chloral hydrate.
Quantification of CoNV
Slit lamp examinations were performed in a blinded man-
ner on day 3, 7, 14, 21 and 28 by a same operator. The
changes in length and area of the corneal neovasculature
and related adverse complications were recorded using a
Canon Cybershot camera (Canon Corporation, Japan).
The corneas were examined and photographed routinely.
The photographs were digitized, and the images were ana-
lyzed using Image J Software. The length of the CoNV
was measured from the edge of the sclera using a reticule
on days 3, 7, 14, 21 and 28 after modeling. The area (A) of
the CoNV was calculated using the following formula:
A = C/12 × π[r2 ‐ (r ‐ l)2], where C is the clock hours of cor-
neal NV coverage on the cornea, l is the average length of
the selected vessels, and r is the radius of the rat cornea.
Immunohistochemistry
The rat eyeballs were harvested and fixed in 4% parafor-
maldehyde. The corneas were excised, embedded in par-
affin, cut into 5-μm sections and then prepared for
hematoxylin and eosin (H&E) staining. The cornea sec-
tions were fixed in acetone. The primary antibodies were
VEGF-A, fms-like tyrosine kinase (VEGFR-1, Flt-1) and
kinase insert domain receptor (VEGFR-2, Flk-1), matrix
metalloproteinase-9 (MMP-9) and intercellular adhesion
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the secondary antibody. Then stained samples were ob-
served and photographed using inverted microscopy.
Western blot
The rats were euthanized, and the corneas were har-
vested from the treated eyes. The corneas were dissected
and frozen at −70°C, then homogenized in ice-cold RIPA
lysis buffer solution (Santa cruz, USA). After being cen-
trifuged for 5 minutes at 12,000 revolutions per minute
(rpm), the supernatants of the samples were collected.
Certain amounts of the protein were separated by elec-
trophoresis on an 8% and 12% sodium dodecyl sulfate-
polyacrylamide gel, and transferred to nitrocellulose
membranes (Invitrogen, San Diego, CA). Then the mem-
branes were blocked using 5% skim milk in TBST
(20 mM Tris, 150 mM NaCl and 0.1% Tween-20) and
incubated overnight with primary antibodies: anti-VEGF
(Santa Cruz, USA), MMP-9 (Abcam, UK), VEGF receptor
1 (Abcam, UK), ICAM-1 (LifeSpan BioSciences, USA)
and VEGF receptor 2 (LifeSpan BioSciences, USA). The
secondary polyclonal antibodies were used to detect
bound primary antibodies: anti-mouse (EMD Millipore,
USA), anti-rabbit (EMD Millipore, USA), and anti-goat
(EMD Millipore, USA). After washing, an enhanced
chemiluminescence solution (ECL reagent: Santa Cruz,
CA) were used to visualize specific lanes.
Statistical analysis
Statistical analysis was performed using IBM SPSS Version
20.0 software (IBM SPSS, Chicago, IL). Experimental data
were analyzed using one-way ANOVA, the Dunnett mul-
tiple comparison test, and independent two-sample t-tests.
All reported P values are 2-sided and P < 0.05 was consid-
ered statistically significant. All results are presented as
the mean ± standard error of the mean. All measurements
were within 95% confidence limits.
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